GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women.
GLP‑1 agonists are associated with a significant reduction in breast cancer incidence in women.
Purpose: Assess the impact of glucagon‑like peptide‑1 (GLP‑1) receptor agonists on breast cancer risk. Methods: A retrospective cohort study of 111,646 women aged 45‑80 with BMI ≥ 25, identified from electronic health records between 2022 and 2025, using propensity‑matched case‑control design. Results: GLP‑1 agonist exposure was associated with a lower incidence of breast cancer (OR 0.695, 95% CI 0.590‑0.819; P < .0001). Conclusion: GLP‑1 agonists may reduce breast cancer incidence; prospective trials are warranted.
Reduction of breast cancer incidence with GLP‑1 agonists offers a potential preventive strategy that leverages existing diabetes and weight‑management medications, but causal inference requires randomized trials.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC